Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
May 16, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) --...
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 02, 2022 16:05 ET
|
Dyne Therapeutics, Inc.
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 - WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Dyne...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 10, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 -- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and...
Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
March 03, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
January 18, 2022 08:00 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
December 02, 2021 08:30 ET
|
Dyne Therapeutics, Inc.
- DYNE-251, Dyne’s First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 - - DYNE-101 IND Submission in DM1 Expected in the First Quarter of 2022 --...
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 04, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne’s Co-lead Candidates into the Clinic - - Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD...
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
October 13, 2021 07:45 ET
|
Dyne Therapeutics, Inc.
- Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - - Event also Features...
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
October 01, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model - - DYNE-251 Achieves...